4811-16-9

Usage

Uses

Used in Nutritional Supplements:
6-Hydroxymethyl-2-methyl-pyridin-3-ol is used as a nutritional supplement to support the body's metabolic processes and maintain overall health. It helps in the conversion of food into energy and supports the synthesis of neurotransmitters, which are essential for proper brain function and mood regulation.
Used in Food Fortification:
In the food industry, 6-Hydroxymethyl-2-methyl-pyridin-3-ol is used as a fortifying agent to enhance the nutritional value of various food products. It helps to ensure that individuals consuming these products receive adequate amounts of vitamin B6, contributing to their overall health and well-being.
Used in Pharmaceutical Applications:
6-Hydroxymethyl-2-methyl-pyridin-3-ol is utilized in the pharmaceutical industry for the development of medications that address vitamin B6 deficiency and its associated symptoms. It is also used in combination with other vitamins and minerals to create multivitamin formulations that support overall health and well-being.
Used in Cosmetics and Personal Care Products:
In the cosmetics and personal care industry, 6-Hydroxymethyl-2-methyl-pyridin-3-ol is used as an ingredient in various products, such as creams, lotions, and shampoos. It helps to maintain healthy skin and hair by promoting the synthesis of essential proteins and supporting the body's natural repair processes.
Used in Animal Nutrition:
6-Hydroxymethyl-2-methyl-pyridin-3-ol is also used in animal nutrition to ensure that livestock and pets receive adequate amounts of vitamin B6. It supports their growth, development, and overall health by promoting proper metabolic processes and maintaining the integrity of their nervous and immune systems.

InChI:InChI=1/C7H9NO2/c1-5-7(10)3-2-6(4-9)8-5/h2-3,9-10H,4H2,1H3

Upstream product

• 1121-25-1 2-methyl-3-pyridinol 
• 50-00-0 formaldehyd 
• 7440-44-0 pyrographite 

Relevant academic research and scientific papers

Evidence for Reagent-Induced Spin-State Switching in Tripodal Fe(II) Iminopyridine Complexes

We present evidence of a spin-state change that accompanies desilylation reactions performed on two related Fe(II) iminopyridine coordination complexes. To probe these systems, we performed titrations with CsF in solution and analyzed the speciation with in situ magnetometry, electrochemistry, and mass spectrometry techniques. We find that pendant tert-butyldimethylsilyl groups are readily cleaved under these conditions, and the resulting desilylated complexes exhibit overall decreased solution magnetic susceptibility values. Density functional theory and ab initio computations probe the impact of substituent identity (prior to- and post-desilylation) on the metal-ligand σ-donor and -acceptor bonding properties. We attribute the observed spin-state changes to the decrease in entropy associated with the conformational freedom of the silylated high-spin complex, resulting in a more favored low-spin state upon desilylation.

Substituted pyridine and pyrimidine derivatives and their use in treating viral infections

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

Does the solid-liquid crystal phase transition provoke the spin-state change in spin-crossover metallomesogens?

Three types of interplay/synergy between spin-crossover (SCO) and liquid crystalline (LC) phase transitions can be predicted: (i) systems with coupled phase transitions, where the structural changes associated to the Cr?LC phase transition drives the spin-state transition, (ii) systems where both transifions coexist in the same temperature region but are not coupled, and (iii) systems with uncoupled phase transitions. Here we present a new family of Fe(II) metallomesogens based on the ligand tris[3-aza-4-((5-C n)(6-R)(2-pyridyl))but-3-enyl]amine, with Cn = hexyloxy, dodecyloxy, hexadecyloxy, octadecyloxy, eicosyloxy, R = hydrogen or methyl (Cn-trenH or Cn-trenMe), which affords examples of systems of types i, ii, and iii. Self-assembly of the ligands Cn-trenH and Cn-trenMe with Fe(A)2·xH2O salts have afforded a family of complexes with general formula [Fe(Cn-trenR)](A) 2· sH2O (s > 0), with A = ClO4 -, F-, Cl-, Br- and I-. Single-crystal X-ray diffraction measurements have been performed on two derivatives of this family, named as [Fe(C6-trenH)](ClO 4)2 (C6-1) and [Fe(C6-trenMe)] (ClO4)2 (C6-2), at 150 K for C6-1 and at 90 and 298 K for C6-2. At 150 K, C6-1 displays the triclinic space group P1, whereas at 90 and at 298 K C6-2 adopts the monoclinic P21/c space group. In both compounds the iron atoms adopt a pseudo-octahedral symmetry and are surrounded by six nitrogen atoms belonging to imino groups and pyridines of the ligands Cn-trenH and C n-trenMe. The average Fe(II)-N bonds (1.963(2) A) at 150 K denote that C6-1 is in the low-spin (LS) state. For C6-2 the average Fe(II)-N bonds (2.007(1) A) at 90 K are characteristic of the LS state, while at 298 K they are typical for the high-spin (HS) state (2.234(3) A). Compound C6-1 and [Fe-(C18-trenH)](ClO 4)2 (C18-1) adopts the LS state in the temperature region between 10 and 400 K, while compound C6-2 and [Fe(Cn-trenMe)](ClO4)2 (n = 12 (C 12-2), 18 (C18-2)) exhibit spin crossover behavior at T1/2 centered around 140 K. The thermal spin transition is accompanied by a pronounced change of color from dark red (LS) to orange (HS). The light-induced excited spin state trapping (LIESST) effect has been investigated in compounds C6-2, C12-2 and C 18-2. The T1/2LIESST is 56 K (C6-2), 48 K (C16-2), and 56 K (C18-2). On the basis of differential scanning calorimetry, optical polarizing microscopy, and X-ray diffraction findings for C18-1, C12-2, and C 18-2 at high temperature a smectic mesophase Sx has been identified with layered structures similar to C6-1 and C 6-2. The compounds [Fe(Cn-trenH)](Cl)2· sH2O (n = 16 (C16-3, s = 3.5, C16-4, s = 0.5, C16-5, s = 0), 18 (C18-3, s = 3.5, C18-4, s = 0.5, C18-5, s = 0), 20 (C20-3, s = 3.5, C20-4, s = 0.5, C20-5, s = 0)) and [Fe(C18-tren)](F) 2·sH2O (C18-6, s = 3.5, C 18-7, s= 0) show a very particular spin-state change, while [Fe(C18-tren)](Br)2·3H2O (C 18-8) together with [Fe(C18-tren)](I)2 (C 18-9) are in the LS state (10-400 K) and present mesomorphic behavior like that observed for the complexes C18-1, C12-2, and C18-2. In compounds Cn-3 50% of the Fe(II) ions undergo spin-state change at T1/2 = 375 K induced by releasing water, and in partially dehydrated compounds (s = 0.5) the Cr→SA phase transition occurs at 287 K (C16-4), 301 K (C18-4) and 330 K (C20-4). For the fully dehydrated materials Cn-5 50% of the Fe(II) ions are in the HS state and show paramagnetic behavior between 10 and 400 K. In the partially dehydrated Cn-4 the spin transition is induced by the change of the aggregate state of matter (solid?liquid crystal). For compound C18-6 the full dehydration to C18-7 provokes the spin-state change of nearly 50% of the Fe(II) ions. The compounds Cn-3 and C18-6 are dark purple in the LS state and become light purple-brown when 50% of the Fe(II) atoms are in the HS state.